|
|---|
|
|
|
|
|
W********g
发帖数: 610 | 1 06/29/2012 Astellas Pharma Inc. ALPMY.PK, ALPMF.PK Mirabegron (NDA) FDA
decision on Mirabegron for proposed treatment of overactive bladder
-News
06/28/2012 Bristol-Myers Squibb Co. BMY ELIQUIS (NDA) FDA decision on
ELIQUIS for prevention of stroke and systemic embolism in patients with
atrial fibrillation
06/27/2012 Arena Pharmaceutical Inc. ARNA Lorcaserin (NDA) FDA decision on
Lorcaserin for proposed treatment of obesity
06/21/2012 Repligen Corp RGEN SecreFlo (NDA) FDA decision on SecreFlo for
detection of pancreatic duct abnormalities
-News
06/10/2012 Navidea Biopharmaceuticals, Inc. NEOP, NAVB Lymphoseek (NDA) FDA
decision on Lymphoseek for proposed use in intraoperative lymphatic mapping
FDA decision date postponed to September 10, 2012
06/08/2012 XENOPORT INC XNPT Horizant (sNDA) FDA decision on Horizant in
addnl indication of post-herpetic neuralgia
06/05/2012 Salix Pharmaceuticals Ltd SLXP Crofelemer 125 mg tablets (NDA)
FDA decision on Crofelemer for control and symptomatic relief of diarrhea in
patients with HIV/AIDS on anti-retroviral therapy -Drug Status
-News
05/31/2012 Repligen Corp RGEN SecreFlo (NDA) FDA panel to review SecreFlo
for detection of pancreatic duct abnormalities
-News
05/24/2012 Pfizer Inc. PFE VYNDAQEL (NDA) FDA panel to review VYNDAQEL for
treating transthyretin familial amyloid polyneuropathy
05/13/2012 Talon Therapeutics, Inc. TLON.OB Marqibo (NDA) FDA decision on
Marqibo in the proposed treatment of adult Philadelphia chromosome-negative
acute lymphoblastic leukemia
-News
05/11/2012 Gilead Sciences Inc. GILD Quad (NDA) FDA panel to review Quad in
potential treatmentof HIV
05/10/2012 Gilead Sciences Inc. GILD Truvada (sNDA) FDA panel to review
Truvada in new indication as HIV preventive therapy
-News
05/10/2012 Arena Pharmaceutical Inc. ARNA Lorcaserin (NDA resubmission) FDA
panel to review Lorcaserin for obesity
05/09/2012 Pfizer Inc. PFE Tofacitinib tablets (NDA) FDA panel to review
Tofacitinib for treatment of adult patients with moderately to severely
active rheumatoid arthritis
05/08/2012 Regeneron Pharmaceuticals REGN Arcalyst (sBLA) FDA panel to
review Arcalyst for addnl indication in preventing gout flares in patients
initiating uric acid-lowering therapy
-News | s**********9
发帖数: 846 | | t****g
发帖数: 3434 | | s******a
发帖数: 318 | | D********9
发帖数: 194 | | c**t
发帖数: 2889 | 6 thanks
【在 W********g 的大作中提到】
: 06/29/2012 Astellas Pharma Inc. ALPMY.PK, ALPMF.PK Mirabegron (NDA) FDA
: decision on Mirabegron for proposed treatment of overactive bladder
:
:
:
: -News
: 06/28/2012 Bristol-Myers Squibb Co. BMY ELIQUIS (NDA) FDA decision on
: ELIQUIS for prevention of stroke and systemic embolism in patients with
: atrial fibrillation
:
|
|
|
|
|
|
|
